Roche enters into a definitive agreement to acquire LumiraDx ' s Point of Care technology combining multiple diagnostic modalities on a single platform

The transformative point of care solution will complement Roche ’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areasLumiraDx ’s technology integrates multiple Point of Care tests on a simple to use single instrument and brings more affordable and accessible testing to patients worldwideUnder the terms of the agreement, Rochewill pay a purchase price of USD 295 million and an additional payment of up to USD 55 millionBasel, 29 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire select parts of the LumiraDx group (NASDAQ GS: LMDX) related to LumiraDx ’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.“The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care.” said Matt Sause, CEO Roche Diagnostics. “LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and techno logies. We believe this will enable better patient access to timely results in decentralised healthcare settings worldwide.”Veronique Ameye, Chief Executive Officer of LumiraDx added, “Since our founding, we have sought to transform community-based healthcare by consolidating multiple Point of Care te...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news